Provided by Tiger Trade Technology Pte. Ltd.

IDEAYA Biosciences

42.58
+2.546.33%
Volume:680.25K
Turnover:28.45M
Market Cap:4.10B
PE:-21.76
High:42.68
Open:40.51
Low:40.06
Close:40.04
52wk High:42.68
52wk Low:23.23
Shares:96.27M
Float Shares:94.37M
Volume Ratio:0.77
T/O Rate:0.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9561
EPS(LYR):-1.2849
ROE:-16.22%
ROA:-11.54%
PB:3.42
PE(LYR):-33.13

Loading ...

Ideaya Biosciences price target raised to $65 from $60 at Truist

TIPRANKS
·
Apr 14

BUZZ-U.S. STOCKS ON THE MOVE-Conagra, Oracle, Replimune

Reuters
·
Apr 14

BUZZ-U.S. STOCKS ON THE MOVE-Allogene Therapeutics, Adobe, Williams-Sonoma

Reuters
·
Apr 13

IDEAYA Biosciences Up Over 17%, on Pace for Largest Percent Increase Since April 2023 -- Data Talk

Dow Jones
·
Apr 13

Wedbush Adjusts Price Target on IDEAYA Biosciences to $58 From $52, Maintains Outperform Rating

MT Newswires Live
·
Apr 13

Ideaya Biosciences rises 22.8%

TIPRANKS
·
Apr 13

IDEAYA Biosciences Shares Rise 13% After Co's Eye Cancer Drug Combo Improves Survival in Trial

THOMSON REUTERS
·
Apr 13

Ideaya Biosciences Stock Jumps 16% on Eye Cancer Therapy Trial Results

Dow Jones
·
Apr 13

IDEAYA Eye Cancer Trial Data Beats Standard Therapy, Stock Soars

Benzinga_recent_news
·
Apr 13

Top Premarket Gainers

MT Newswires Live
·
Apr 13

Stock Track | IDEAYA Biosciences Soars 31.15% in Pre-market on Positive Phase 2/3 Trial Results for Eye Cancer Drug

Stock Track
·
Apr 13

Ideaya Biosciences Shares Jump on Trial Results

Dow Jones
·
Apr 13

BUZZ-IDEAYA Biosciences surges after eye cancer drug combo improves survival in trial

Reuters
·
Apr 13

Ideaya Biosciences, Servier announce topline results from OptimUM-02 trial

TIPRANKS
·
Apr 13

U.S. Stocks to Watch: Goldman Sachs, SanDisk, Exxon Mobil, Nvidia, Ideaya, and More

Tiger Newspress
·
Apr 13

Ideaya eye cancer drug meets main goal of mid-to-late-stage trial

Reuters
·
Apr 13

IDEAYA says darovasertib-crizotinib trial cuts progression risk 58% in metastatic uveal melanoma

Reuters
·
Apr 13

IDEAYA Biosciences Shares Gain 18% Premarket Ahead of Data Release for Its Experimental Cancer Drug

THOMSON REUTERS
·
Apr 13

IDEAYA Biosciences Inc - Trial Met Primary Endpoint Showing Statistically Significant Improvement in Median Pfs by Bicr

THOMSON REUTERS
·
Apr 13

IDEAYA Biosciences Inc - Nda Submission Planned for Second Half of 2026 to Support U.S. Accelerated Approval

THOMSON REUTERS
·
Apr 13